HBSP (USA)
-
Framework for Risk Management
Froot, Kenneth A.; Scharfstein, David S.; Stein, Jeremy C.Article HBS-94604-EStrategyIn recent years, managers have become aware of how their companies can be buffeted by risks beyond their control. To insulate themselves from such risks, many companies are turning to the derivatives markets, taking advantage of instruments like forwards, futures, options, and swaps. Although heavily involved in risk management, most companies do not have clear goals underlying their hedging programs. Without such goals, using derivatives can be ...Starting at €8.20
-
Process of Scientific Discovery, Teaching Note
Fleming, Lee; Marin, AlexandraTeaching Note HBS-607126-EEntrepreneurshipTeaching Note. An abstract is not available for this product.Starting at €0.00
-
Agion Technologies
Fleming, Lee; Perry, Thomas DCase HBS-609070-EService and Operations ManagementStarting at €8.20
-
OnDeck Capital, Inc.
Scharfstein, David S.; Begenau, JulianeCase HBS-219100-EFinanceStarting at €8.20
-
Live Oak Bank
Scharfstein, David S.; Williams, Emily; O'Brien, ShawnCase HBS-219103-EFinanceStarting at €8.20
-
Oaktree and the Restructuring of CIT Group (B)
Ivashina, Victoria; Scharfstein, David S.Case HBS-214036-EFinanceThis supplement presents the actual terms of the rescue financing provided by a group of private investors to CIT. It is intended to be distributed at the end of the discussion of "Oaktree and the Restructuring of CIT Group (A)" (HBS No. 214-035) and can be used as background to reflect on the students' proposal of financing terms for the $3 billion rescue financing of CIT.Starting at €5.74
-
Momentive Performance Materials, Inc., Teaching Note
Ivashina, Victoria; Scharfstein, David S.Teaching Note HBS-214057-EFinanceTo maximize their effectiveness, color cases should be printed in color. Teaching note for case 210081.Starting at €0.00
-
The Proposed Merger of M&T Bank and Hudson City Bancorp (B)
Scharfstein, David S.Case HBS-216047-EFinanceStarting at €5.74
-
Zest AI: Machine Learning and Credit Access
Scharfstein, David S.; Gilland, RyanCase HBS-224033-EFinanceStarting at €8.20
-
Vertex Pharmaceuticals: R&D Portfolio Management (A)
Pisano, Gary P.; Fleming, Lee; Strick, Eli PeterCase HBS-604101-EService and Operations ManagementVertex Pharmaceuticals, Inc., a drug discovery company that recently decided to pursue a vertically integrated business model, chose to build up its clinical development and commercial capabilities and infrastructure. For the first time in its history, Vertex will select two drug candidates from its internal research portfolio of four projects to develop on its own, without the help of strategic partners. CEO Joshua Boger and President Vicki Sato...Starting at €8.20